| Literature DB >> 33287423 |
Han Young Eom1, Seok-In Jang1, Jong-Hwa Lee1.
Abstract
Breast milk contains human milk oligosaccharides (HMOs), including sialyllactose (SL). SL is composed of sialic acid and lactose, and is divided into 3'-SL and 6'-SL according to the binding position. SL has immunoprotective effects against bacteria and viruses, and acts as a probiotic in the gastrointestinal tract. In this study, we developed a bioanalytical method for simultaneous analysis of 3'-SL and 6'-SL in liver and kidney tissues of Yucatan minipigs using liquid chromatography-tandem mass spectrometry (LC-MS/MS) under conditions optimized in our previous study. LC-MS/MS was performed using a hydrophilic interaction liquid chromatography (HILIC) column (50 mm × 2.1 mm, 3 μm) with a mobile phase consisting of 10 mM ammonium acetate in water (pH 4.5) and acetonitrile with gradient elution at a flow rate of 0.3 mL/min. A surrogate matrix method using water was applied for analysis of endogenous SL. The developed method was validated with regard to selectivity, linearity, precision, accuracy, the matrix effect, recovery, parallelism, dilution integrity, carryover, and stability according to the US Food and Drug Administration guidelines. We performed a tissue distribution study of minipigs, and analyzed liver and kidney tissues using the developed method to determine the tissue distribution of 3'-SL and 6'-SL. The tissue concentrations of 3'-SL and 6'-SL were readily measurable, suggesting that the method would be useful for evaluating the tissue distributions of these compounds in minipigs.Entities:
Keywords: LC-MS/MS; method validation; minipig; sialyllactose; tissue
Mesh:
Substances:
Year: 2020 PMID: 33287423 PMCID: PMC7731434 DOI: 10.3390/molecules25235721
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The chemical structure and product ion scan spectra of (A) 3′-sialyllactose, (B) 6′-sialyllactose, and (C) internal standard.
Assessment of selectivity for 3′-SL and 6′-SL.
| Samples | Peak Area Ratio | |||
|---|---|---|---|---|
| 3′-SL | 6′-SL | |||
| Quant a/Qual1 b | Quant/Qual2 c | Quant/Qual1 | Quant/Qual2 | |
| HQC d | 120 | 2290 | 1.83 | 18.2 |
| Liver | 116 | 2000 | 1.82 | 17.3 |
| Kidney | 119 | 2420 | 1.69 | 16.3 |
| Mean | 119 | 2240 | 1.78 | 20.0 |
| SD e | 2 | 215 | 0.08 | 1.0 |
| CV(%) f | 1.7 | 9.6 | 4.3 | 4.9 |
a Quant = The peak area at the quantification ion transition (m/z 632.4→290.0). b Qual1 = The peak area at the first qualification ion transition (m/z 632.4→572.2). c Qual2 = The peak area at the second qualification ion transition (m/z 632.4→469.7). d HQC = high quality control. e SD = standard deviation. f CV (%) = standard deviation of the concentration/mean concentration × 100.
Figure 2Multiple-reaction monitoring (MRM) chromatograms of (A) surrogate matrix and (B) liver and kidney: double blank, zero blank, and lower limit of quantification (LLOQ) in surrogate matrix, and double blank, zero blank, blank, and pharmacokinetic application samples for the liver and kidney.
Intra- and inter-day accuracy and precision data.
| 3′-SL | 6′-SL | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| LLOQ | LQC | MQC | HQC | LLOQ | LQC | MQC | HQC | ||
| Nominal Concentration (ng/g) | 20 | 60 | 1500 | 15,000 | 20 | 60 | 1500 | 15,000 | |
| (A) Liver | |||||||||
| Intra-day | Mean estimated conc. (ng/g) | 20.1 | 59.5 | 1460 | 14,900 | 20.5 | 58.3 | 1540 | 15,300 |
| RE (%) a | 0.3 | −0.8 | −2.7 | −0.7 | 2.4 | −2.8 | 2.7 | 2.0 | |
| CV (%) b | 3.6 | 2.7 | 2.1 | 0.5 | 7.2 | 4.7 | 1.4 | 1.7 | |
| Inter-day | Mean estimated conc. (ng/g) | 21.5 | 59.9 | 1420 | 14,300 | 21.4 | 59.4 | 1520 | 15,400 |
| RE (%) | 7.5 | −0.2 | −5.3 | −4.7 | 7.2 | −0.9 | 1.3 | 2.7 | |
| CV (%) | 8.5 | 3.0 | 4.1 | 4.9 | 10.0 | 4.5 | 2.9 | 4.0 | |
| (B) Kidney | |||||||||
| Intra-day | Mean estimated conc. (ng/g) | 20.1 | 59.5 | 1470 | 14,200 | 20.5 | 58.3 | 1590 | 14,900 |
| RE (%) | 0.3 | −0.8 | −2.0 | −5.3 | 2.4 | −2.8 | 6.0 | −0.7 | |
| CV (%) | 3.6 | 2.7 | 1.0 | 3.6 | 7.2 | 4.7 | 2.3 | 2.6 | |
| Inter-day | Mean estimated conc. (ng/g) | 21.5 | 59.9 | 1460 | 14,300 | 21.4 | 59.4 | 1600 | 15,400 |
| RE (%) | 7.5 | −0.2 | −2.7 | −4.7 | 7.2 | −0.9 | 6.7 | 2.7 | |
| CV (%) | 8.5 | 3.0 | 3.4 | 3.8 | 10.0 | 4.5 | 8.3 | 4.5 | |
a RE (%) = (calculated concentration − theoretical concentration)/theoretical concentration × 100. b CV (%) = standard deviation for the concentration/mean concentration × 100.
Matrix effect and recovery data.
| 3′-SL | 6′-SL | ||||||
|---|---|---|---|---|---|---|---|
| LQC | MQC | HQC | LQC | MQC | HQC | ||
| Nominal Concentration (ng/g) | 60 | 1500 | 15,000 | 60 | 1500 | 15,000 | |
| (A) Matrix factor (internal standard-normalized, | |||||||
| Liver | Mean | 1.15 | 0.952 | 0.993 | 1.10 | 1.06 | 1.12 |
| CV (%) | 12.4 | 5.6 | 3.6 | 15.7 | 8.2 | 4.2 | |
| Kidney | Mean | 0.853 | 0.958 | 0.993 | 0.889 | 0.965 | 0.996 |
| CV (%) | 7.3 | 1.2 | 0.4 | 20.9 | 2.1 | 1.3 | |
| (B) Recovery ( | |||||||
| Liver | Mean (%) | 84.8 | 80.5 | 60.0 | 85.8 | 80.8 | 59.2 |
| CV (%) | 4.7 | 10.1 | 7.2 | 27.8 | 10.0 | 6.9 | |
| Kidney | Mean (%) | 123.6 | 95.9 | 90.3 | 115.7 | 98.0 | 91.2 |
| CV (%) | 4.9 | 4.2 | 4.4 | 14.9 | 2.9 | 4.3 | |
Assessment of parallelism between surrogate matrix and authentic matrix.
| 3′-SL | 6′-SL | |||||
|---|---|---|---|---|---|---|
| LQC | MQC | HQC | LQC | MQC | HQC | |
| Nominal Concentration (ng/g) | 60 | 1500 | 15,000 | 60 | 1500 | 15,000 |
| (A) Liver | ||||||
| Endogenous conc. (ng/g) a | 324 | 324 | 324 | 117 | 117 | 117 |
| Adjusted QC conc. (ng/g) b | 384 | 1824 | 15,324 | 177 | 1617 | 15,117 |
| Mean estimated conc. (ng/g) | 357 | 1701 | 14,368 | 168 | 1543 | 14,105 |
| RE (%) | −7.2 | −6.8 | −6.2 | −5.5 | −4.6 | −6.7 |
| CV (%) | 1.2 | 0.6 | 0.4 | 5.6 | 1.9 | 1.4 |
| (B) Kidney | ||||||
| Endogenous conc. (ng/g) | 66.3 | 66.3 | 66.3 | 58.9 | 58.9 | 58.9 |
| Adjusted QC conc. (ng/g) | 126 | 1566 | 15,066 | 119 | 1559 | 15,059 |
| Mean estimated conc. (ng/g) | 108 | 1445 | 14,068 | 108 | 1392 | 13,625 |
| RE (%) | −14.8 | −7.8 | −6.6 | −9.5 | −10.7 | −9.5 |
| CV (%) | 6.0 | 1.3 | 1.4 | 7.9 | 2.5 | 0.7 |
a The endogenous concentration in the authentic matrix was calculated from the x-intercept of the calibration curve established with addition of internal standard to authentic matrix. b The adjusted QC concentration was calculated as the sum of the endogenous concentration and the theoretical concentration of sialyllactose.
Figure 3Calibration curves of (A) 3′-SL and (B) 6′-SL for parallelism assessment in minipig liver and kidney and surrogate matrix. The calibration curves of liver and kidney were constructed by the standard addition method.
Biological sample stability.
| Liver | Kidney | |||||||
|---|---|---|---|---|---|---|---|---|
| 3′-SL | 6′-SL | 3′-SL | 6′-SL | |||||
| LQC | HQC | LQC | HQC | LQC | HQC | LQC | HQC | |
| Nominal Concentration (ng/g) a | 339 | 15,000 | 118 | 15,000 | 62.1 | 15,000 | 55.6 | 15,000 |
| (A) Benchtop (room temperature for 4 h) and long-term stability (storage at −80 °C for 34 days, | ||||||||
| Mean estimated concentration (ng/g) | 313 | 14,200 | 122 | 14,500 | 56.4 | 14,100 | 50.0 | 14,000 |
| RE (%) | −7.6 | −5.3 | 3.7 | −3.3 | −9.2 | −6.0 | −10.1 | −6.7 |
| CV (%) | 1.0 | 0.7 | 10.5 | 0.8 | 11.2 | 2.7 | 11.7 | 2.5 |
| (B) Post-preparative stability at 10 °C for 21 h ( | ||||||||
| Mean estimated concentration (ng/g) | 334 | 14,600 | 114 | 16,300 | 55.7 | 14,500 | 55.9 | 15,700 |
| RE (%) | −1.3 | −2.7 | −3.1 | 8.7 | −10.2 | −3.3 | 0.5 | 4.7 |
| CV (%) | 2.3 | 1.0 | 10.5 | 0.6 | 0.7 | 1.8 | 10.9 | 1.6 |
| (C) Freeze/thaw stability (four cycles, | ||||||||
| Mean estimated concentration (ng/g) | 319 | 140,00 | 127 | 14,200 | 60.1 | 13,800 | 51.8 | 13,600 |
| RE (%) | −5.8 | −6.7 | 7.6 | −5.3 | −3.2 | −8.0 | −6.8 | −9.3 |
| CV (%) | 2.7 | 0.8 | 7.7 | 1.2 | 5.9 | 4.4 | 4.4 | 4.2 |
a The nominal concentration of LQC was determined from the background SL concentration in each matrix. b Benchtop stability was assessed in samples stored at −80 °C for 34 days.
Tissue to plasma (T/P) concentration ratios of 3′-SL and 6′-SL at 2 h after intravenous administration of a dose of 12.5 mg/kg.
| Compounds | Tissue Concentration (ng/g) | T/P Ratio | |||
|---|---|---|---|---|---|
| Liver | Kidney | Plasma | Liver/Plasma | Kidney/Plasma | |
| 3′-SL | 2550 | 22,300 | 21,500 | 0.12 | 1.0 |
| 6′-SL | 3030 | 27,000 | 21,000 | 0.14 | 1.3 |